TY - JOUR T1 - A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration JF - medRxiv DO - 10.1101/2020.06.24.20134288 SP - 2020.06.24.20134288 AU - Shoji Hashimoto AU - Heita Kitajima AU - Tsuyoshi Arai AU - Yoshitaka Tamura AU - Takayuki Nagai AU - Hiroshi Morishita AU - Hiroto Matsuoka AU - Yuki Han AU - Seijiro Minamoto AU - Tomonori Hirashima AU - Tomoki Yamada AU - Yozo Kashiwa AU - Makoto Kameda AU - Seiji Yamaguchi AU - Kazuko Uno AU - Emi Nakayama AU - Tatsuo Shioda AU - Kazuyuki Yoshizaki AU - Sujin Kang AU - Tadamitsu Kishimoto AU - Toshio Tanaka Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/30/2020.06.24.20134288.abstract N2 - We administered tocilizumab into 13 severe-to-critically ill patients with coronavirus disease 2019 (COVID-19) for compassionate use in combination with potential anti-viral agents in those who required an oxygen supply and showed increased laboratory inflammatory markers such as C-reactive protein (CRP) and ferritin. One injection of tocilizumab led to rapid improvements in clinical features, inflammatory findings, and oxygen supply in seven patients with severe COVID-19 and substantial amelioration in two patients who were critically ill, whereas four patients, who exhibited rapidly worsened respiratory function, required artificial ventilatory support even after tocilizumab treatment. Three of these four patients ultimately recovered from deterioration after methylprednisolone treatment. Administration of tocilizumab did not affect viral elimination nor IgG production specific for the virus. Compared with well-responding patients, rapidly-worsened patients showed a significantly higher ratio of ferritin vs. CRP. These findings suggest that tocilizumab has beneficial effects in severe-to-critically ill patients with COVID-19; however, in some cases, addition of methylprednisolone is required for disease rescue.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis manuscript reports findings of observational research of compassionate use of tocilizumab.Funding StatementNo funding was received for this report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board of Osaka Habikino Medical Center (Approved ID: 150-7).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe availability of all data were included in the manuscript. ER -